Caplacizumab is a Monoclonal Antibody owned by Sanofi, and is involved in 13 clinical trials, of which 12 were completed, and 1 is ongoing.

Caplacizumab acts as von Willebrand Factor inhibitor. It binds with high affinity to the A1 domain of von Willebrand Factor (vWF) and thereby blocks the interactions between platelets and vascular collagen. ALX-0681 is an anti-vWF nanobody, which inhibits von Willebrand factor (vWF) and prevent unwanted thrombus formation in vessels under high shear conditions without interfering with desirable haemostasis and to minimize bleeding complications.

The revenue for Caplacizumab is expected to reach a total of $6.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Caplacizumab NPV Report.

Caplacizumab was originated by Ablynx and is currently owned by Sanofi.

Caplacizumab Overview

Caplacizumab (Cablivi) is an anti-thrombotic agent. It is formulated as lyophilized powder for solution and solution for intravenous and subcutaneous route of administration. Cablivi is indicated for the treatment of adults experiencing an episode of acquired  thrombotic thrombocytopenic purpura. Cablivi (caplacizumab) is indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange and immunosuppressive therapy. It is administered as an intravenous and subcutaneous formulation. The drug candidate is a nanobody targeted against von Willebrand Factor (vWF), a protein found in the blood that acts at a very early stage in the coagulation cascade, namely platelet adhesion. It was also under development for the treatment of acute coronary syndrome (ACS).

Sanofi Overview

Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi‘s R&D efforts focus on advancing a combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.

The company reported revenues of (Euro) EUR39,175 million for the fiscal year ended December 2021 (FY2021), an increase of 4.8% over FY2020. In FY2021, the company’s operating margin was 20.7%, compared to an operating margin of 37.8% in FY2020. In FY2021, the company recorded a net margin of 15.9%, compared to a net margin of 32.9% in FY2020. The company reported revenues of EUR13,138 million for the third quarter ended September 2022, a decrease of 36.8% over the previous quarter.

Quick View – Caplacizumab

Report Segments
  • Innovator (NME)
Drug Name
  • Caplacizumab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Cardiovascular
  • Hematological Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.